Kaposi’s varicelliform eruption following brentuximab vedotin chemotherapy is associated with robust anti-tumor response in an advanced mycosis fungoides patient

Zaw H Phyo,Sima Rozati,Sahar Soleimani,Powell Perng,Jun Kang,Richard Ambinder

doi:10.15761/hmo.1000224

Abstract

Kaposi’s varicelliform eruption following brentuximab vedotin chemotherapy is associated with robust anti-tumor response in an advanced mycosis fungoides patient

Highlights

Kaposi varicelliform eruption (KVE, known as eczema herpeticum) refers to a diffuse, viral skin infection which usually manifests in patients with an existing chronic inflammatory skin disease, classically atopic dermatitis
A 52-year-old African American woman who was recently diagnosed with stage IVA1 Mycosis fungoides (MF) (T3NxMxB2b) with skin punch biopsy demonstrating no evidence of large cell transformation or follicular tropism with occasional CD30+ cells presented to the infusion center for her second cycle of brentuximab vedotin
We presented a patient with advanced MF who developed diffuse skin erosions and ulcerations consistent with KVE after her first cycle of brentuximab vedotin treatment

Summary

Case Report

Kaposi’s varicelliform eruption following brentuximab vedotin chemotherapy is associated with robust anti-tumor response in an advanced mycosis fungoides patient. Zaw H Phyo, Powell Perng, Sahar Soleimani, Jun Kang, Richard Ambinder and Sima Rozati1* 1Department of Dermatology, Johns Hopkins University, Baltimore, MD, USA 2Department of Radiology, Johns Hopkins University, Baltimore, MD, USA 3Department of Oncology, Johns Hopkins University, Baltimore, MD, USA

Introduction

Findings

Discussion